CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.
  
  LEARNING OBJECTIVES

  • Evaluate the results of genomic assays and other relevant patient- and treatment-related factors to personalize adjuvant systemic therapy for newly diagnosed ER-positive, HER2-negative, lymph node-negative or node-positive breast cancer.
  • Comprehend available findings with CDK4/6 inhibitors in localized ER-positive, HER2-negative breast cancer, and assess the current role of these agents as a component of adjuvant treatment.
  • Individualize the selection and sequence of systemic therapy for patients with newly diagnosed ER-positive metastatic breast cancer (mBC), considering clinical presentation (eg, age, menopausal status, comorbidities, extent and sites of disease), prior treatment course (eg, de novo metastatic disease, type and duration of adjuvant therapy) and psychosocial status.
  • Appraise available research data with commercially available CDK4/6 inhibitors in the treatment ER-positive mBC, and optimally incorporate these agents into patient care.
  • Recognize the frequency of phosphoinositide-3 kinase pathway mutations in patients with ER-positive mBC, and employ evidence-based approaches to targeting these aberrations in patients with ER-positive, HER2-negative, PIK3CA-mutated disease.
  • Appreciate published efficacy and safety data with PARP inhibitors for localized or metastatic breast cancer harboring BRCA1/2 mutations, and consider the diagnostic and therapeutic implications for nonresearch care.
  • Assess ongoing clinical studies evaluating novel agents and treatment strategies under development for ER-positive breast cancer, and counsel patients about the potential benefits of trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Erica Mayer, MD, MPH
  Director of Breast Cancer Clinical Research
  Breast Oncology Center
  Dana-Farber Cancer Institute
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Lilly, Novartis.
  
  Ruth O’Regan, MD
  Chair, Department of Medicine
  Charles A Dewey Professor of Medicine
  University of Rochester
  Rochester, New York
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Lilly, Novartis, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, Exact Sciences Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, MacroGenics Inc, Novartis, Pfizer Inc, Puma Biotechnology Inc; Contracted Research: Novartis, Puma Biotechnology Inc; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc; Nonrelevant Financial Relationship: Criterium.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GSK, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, Lilly, Novartis, Sanofi, and TerSera Therapeutics LLC.
  
  Release date: January 2023
  Expiration date: January 2024